InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,528.00
(
0.90%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
72.91
(
0.00%
)
Bitcoin
69,430.01
(
-0.07%
)
Post# of 253509
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120657
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 86834

Tuesday, 06/08/2010 3:43:22 AM

Tuesday, June 08, 2010 3:43:22 AM

Post# of 253509
Merck KGaA resubmits Cladribine NDA in RRMS:

http://www.reuters.com/article/idCNLDE62O0CG20100608

The FDA issued a Refusal to File letter in Nov 2009 in response to the original NDA submission (#msg-44040202). Merck KGaA refused to divulge what the problem was, leading to speculation that the FDA had insisted on another phase-3 trial (#msg-46949655, #msg-46954975).

Merck KGaA expects a ruling on Cladribine from the EMEA in 3Q10.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up